Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening
We successfully established PDOs from melanoma brain metastases surgical specimens, which exhibited a consistent histological and mutational profile with the parental tissue. Using FDA-approved <i>BRAF</i> and <i>MEK</i> inhibitors, our data demonstrate the feasibility of employing MBM-PDOs for targeted-therapy in vitro testing.
Authors
- Gerrit H. Gielen (ORCID: https://orcid.org/0000-0002-2707-0290)
- Michael Hölzel
- Mohammed Banat (ORCID: https://orcid.org/0000-0001-7986-5215)
- Anna‐Lena Wulf
- Glen Kristiansen (ORCID: https://orcid.org/0000-0003-4149-5487)
- Erdem Güresir (ORCID: https://orcid.org/0000-0001-8319-0847)
- Hartmut Vatter (ORCID: https://orcid.org/0000-0001-9999-7282)
- Judith Sirokay (ORCID: https://orcid.org/0000-0003-3945-845X)
- Matthias Schneider (ORCID: https://orcid.org/0000-0002-6025-7479)
- Torsten Pietsch (ORCID: https://orcid.org/0000-0003-0763-6506)
- Racha Hosni (ORCID: https://orcid.org/0009-0008-6505-5527)
- Marieta Toma (ORCID: https://orcid.org/0000-0002-4803-3712)
- Motaz Hamed (ORCID: https://orcid.org/0000-0003-4828-7496)
- Anne Fröhlich (ORCID: https://orcid.org/0000-0002-9156-309X)
- Saif-Eldin Abedellatif (ORCID: https://orcid.org/0009-0008-1214-6177)
- Andreas Waha
Institutions
- University Hospital Bonn (DE)
Publication Details
- Journal
- Pharmaceutics
- Published
- 2024-08-05
- DOI
- https://doi.org/10.3390/pharmaceutics16081042
- Citations
- 5
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Deutsche Krebshilfe